The renin-angiotensin-aldosterone system in kidney diseases of cats and dogs.

RAAS inhibitors effectively manage hypertension and proteinuria in CKD but may not slow disease progression.

The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in the pathophysiology of kidney diseases in cats and dogs. While RAAS inhibitors are effective in managing comorbidities like systemic hypertension and renal proteinuria, their impact on the progression of chronic kidney disease (CKD) remains uncertain. Studies have shown variable activation of circulating RAAS in animals with kidney diseases, with high interindividual variability. Advancements have introduced the concept of an "alternative" RAAS and tissue-specific renin-angiotensin systems, including the intrarenal RAS, which is recognized as a significant regulator of kidney function and disease. However, data on the intrarenal RAS in cats and dogs with kidney diseases are limited, though existing studies suggest its activation. Further research into the circulating and intrarenal RAAS, and their interplay in kidney diseases of companion animals, is essential to develop or refine future treatment strategies. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39672318/?utm_source=openai))

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.